- CORRESPONDENCE
A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Medicine 28, 1983-1984 (2022)
doi: https://doi.org/10.1038/d41591-022-00077-1
Author contributions
L.B.L.N., J.G. and O.L. are the principal investigators of the study and wrote the manuscript. L.B.L.N. prepared the first draft. L.M., C.D. and J.K.M. designed the methodology of the protocol and edited the manuscript. C.D., E.T., T.S., B.A., J.K.W., D.M. and X.L. oversaw the analysis of data and biological samples of the study and edited the manuscript. C.T., A.T., I.M.O.P., E.T., A.R. and L.R. oversaw the management and coordination responsibility of the research. All authors reviewed the manuscript.
Competing interests
L.B.L.N. has received personal fees as a speaker or consultant from Sanofi and Pfizer. O.L. has received personal fees from Sanofi Pasteur; grants, personal fees, and non-financial support from Pfizer, Janssen, and Sanofi Pasteur–Merck Sharp & Dohme; and grants and non-financial support from GlaxoSmithKline. J.G. has received research grants from Gilead Sciences and Merck Sharp & Dohme and personal fees from Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme, Janssen, Theratechnologies and AstraZeneca. T.S. has received unrestricted research grants from AstraZeneca, Bayer, Boehringer, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, Novartis and Sanofi and personal fees from Ablative Solutions, Air Liquide, AstraZeneca, Novartis, 4 living Biotech and Sanofi, for participation on Advisory or data safety monitoring boards, and from Servier and Novartis, for lectures.
References
Petersen, E. et al. Infect. Dis. Clin. North Am. 33, 1027–1043 (2019).
World Health Organization. https://www.who.int/emergencies/disease-outbreak-news/item/2022–DON385 (21 May 2022).
Reed, K.D. et al. N. Engl. J. Med. 350, 342–350 (2004).
Adler, H. et al. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00228-6 (2022).
Rao, A.K. et al. MMWR Morb. Mortal. Wkly. Rep. 71, 734–742 (2022); https://www.cdc.gov/mmwr/volumes/71/wr/mm7122e1.htm
Pittman, P.R. et al. N. Engl. J. Med. 381, 1897–1908 (2019).
Hatch, G.J. et al. J. Virol. 87, 7805–7815 (2013).
UK Health Security Agency. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1083791/Recommendations-for-pre-and-post-exposure-vaccination-during-a-monkeypox-incident-17-june-2022.pdf (17 June 2022).
Keckler, M.S. et al. Vaccines 8, 396 (2020).
Santé Publique France. https://www.santepubliquefrance.fr/content/download/437302/file/def_cas_CAT_monkeypox_19052022.pdf (2022).